OncoMatch/Clinical Trials/NCT07764978
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Is NCT07764978 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for newly diagnosed multiple myeloma.
Treatment: AZD0120 · Daratumumab · Dexamethasone · Isatuximab · Lenalidomide · Bortezomib · Cyclophosphamide · Fludarabine — This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function for CAR-T cell treatment
Liver function
adequate organ function for CAR-T cell treatment
adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Gilbert, Arizona
- Research Site · Phoenix, Arizona
- Research Site · Tucson, Arizona
- Research Site · Orange, California
- Research Site · Santa Monica, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07764978 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages